Select to order medicines [Delhi/NCR /Bangalore /Chennai /Bhubaneswar /Mumbai]
Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use of the drug in pregnant women clearly outweigh potential benefits.
Studies in breastfeeding mothers have demonstrated that there is significant and documented risk to the infant based on human experience, or it is a medication that has a high risk of causing significant damage to an infant. The risk of using the drug in breastfeeding women clearly outweighs any possible benefit from breastfeeding. The drug is contraindicated in women who are breastfeeding an infant.
Typical usage: Primary hypercholesterolaemia, heterozygous familial hypercholesterolaemia, homozygous familial hypercholesterolaemia or combined hyperlipidaemia.
Side Effects: Flatulence, diarrhoea, nausea, vomiting, anorexia, xerostomia, angioedema, myalgia, rash, pruritus, alopecia, allergy, infection, chest pain.
Drug Interaction: Atorvastatin is known to interact with other drugs like alvimopan, atazanavir, boceprevir, carbamazepine, clarithromycin, cyclosporine, dronedarone, erythromycin, etravirine, ketoconazole, nefazodone. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.
Mechanism Of Action: Atorvastatin selectively and competitively inhibits the hepatic enzyme HMG-CoA reductase. As HMG-CoA reductase is responsible for converting HMG-CoA to mevalonate in the cholesterol biosynthesis pathway, this results in a subsequent decrease in hepatic cholesterol levels. Decreased hepatic cholesterol levels stimulates upregulation of hepatic LDL-C receptors which increases hepatic uptake of LDL-C and reduces serum LDL-C concentrations.
Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
There are no controlled studies in breastfeeding women, however the risk of untoward effects to a breastfed infant is possible; or, controlled studies show only minimal non-threatening adverse effects. Drugs should be given only if the potential benefit justifies the potential risk to the infant.
Typical usage: Hypercholesterolaemia, hyperlipoproteinaemia, prophylaxis of NSAID-associated gastric or duodenal ulcer.
Side Effects: Hepatitis, rhabdomyolysis, headache, diarrhea, myalgia, constipation, skin rashes, impotence, decrease in libido.
Drug Interaction: Fenofibrate is known to interact with other drugs like Acenocoumarol, Anisindione, Cerivastatin, Dicumarol, Lovastatin, Pravastatin. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.
Mechanism Of Action: Fenofibrate exerts its therapeutic effects through activation of peroxisome proliferator activated receptor a (PPARa). This increases lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase and reducing production of apoprotein C-III.
No substitutes found